Literature DB >> 9244832

[Interferon therapy and autoimmunity].

J Fritzsch1, J Krug, H J Heberling.   

Abstract

The treatment of viral hepatitis or malignomas with interferon (IFN) can increase the incidence of autoimmune disease. This paper reviews published case and study reports. The incidence of overt autoimmune diseases under IFN treatment is about 3%. Autoantibodies can be detected in 23% of the patients. Autoimmune thyroid diseases are the most frequent ones, but nearly all autoimmune diseases can occur. Beside benign and reversible courses chronic developments and lethal outcomes are possible. Actual concepts concerning the pathogenesis of IFN-associated autoimmunity include induction of MHC and other molecules as well as the modulation of lymphocyte functions. Clinical and paraclinical controls are necessary under treatment with IFN and during follow-up.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9244832     DOI: 10.1007/bf03045081

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  97 in total

1.  [Autoimmune hepatitis type 1 revealed during treatment with interferon].

Authors:  A Tran; C Beusnel; M L Montoya; V Lussiez; X Hébuterne; P Rampal
Journal:  Gastroenterol Clin Biol       Date:  1992

2.  Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report.

Authors:  N P Sauter; M B Atkins; J W Mier; R M Lechan
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

3.  Induction of hyperthyroidism by interferon-alpha-2b.

Authors:  M Schultz; R Müller; A von zur Mühlen; G Brabant
Journal:  Lancet       Date:  1989-06-24       Impact factor: 79.321

Review 4.  Mechanisms of action of interferons.

Authors:  M Peters
Journal:  Semin Liver Dis       Date:  1989-11       Impact factor: 6.115

5.  Immune thrombocytopenia following alpha-interferon therapy in patients with cancer.

Authors:  P McLaughlin; M Talpaz; J R Quesada; A Saleem; B Barlogie; J U Gutterman
Journal:  JAMA       Date:  1985-09-13       Impact factor: 56.272

6.  Two cases of hypothyroidism associated with alpha-interferon therapy.

Authors:  Y Taniguchi; T Murakami; K Nakanishi; M Tamai; B Matsuura; T Masumoto; M Onji; J Tajiri; S Noguchi; Y Ohta
Journal:  Intern Med       Date:  1992-03       Impact factor: 1.271

7.  Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis.

Authors:  G Saracco; A Touscoz; M Durazzo; F Rosina; E Donegani; L Chiandussi; V Gallo; R Petrino; A G De Micheli; A Solinas
Journal:  J Hepatol       Date:  1990-11       Impact factor: 25.083

8.  Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.

Authors:  J C Becker; B Winkler; S Klingert; E B Bröcker
Journal:  Cancer       Date:  1994-03-15       Impact factor: 6.860

9.  Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia.

Authors:  A I Radin; P Buckley; T P Duffy
Journal:  Hematol Pathol       Date:  1991

10.  Psoriasis and alpha-interferon.

Authors:  J R Quesada; J U Gutterman
Journal:  Lancet       Date:  1986-06-28       Impact factor: 79.321

View more
  1 in total

1.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.